Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

Congress
Main Content

2024 Case Study / Case Report Abstracts

Poster Hall (Exhibit Hall A)
10:00 - 17:30

Open AllClose All
Saturday, September 28
1- Brain De-Ironization with Nasal Spray of Iron Chelator in Treatment of Multiple System Atrophy, a Case Trial
14- Role of the Alpha-synuclein Seed Amplification Assay in Parkinson’s Disease Clinical Trials: A Case Report of Multiple System Atrophy Misdiagnosed as Parkinson’s Disease
22- Multiple System Atrophy in a Patient with Normal Pressure Hydrocephalus
30- Lyme disease presenting as a rapidly progressive MSA-C look alike
36- Familial Multiple System Atrophy-Mimics: Importance of Comprehensive Evaluation
37- Heterogeneity of multiple system atrophy with an analysis of the clinical case
38- Posterior Fossa Arachnoid Cysts In Two Patients With Suspected Multiple System Atrophy – Cerebellar Type
50- Paraneoplastic neurological syndrome mimicking a progressive supranuclear palsy: a case series
77- Progressive freezing of gait in atypical parkinsonism. A Possible Progressive Supranuclear Palsy phenotype.
78- PSP: a Clinical Case
80- Pisa Syndrome as an early presenting feature of Corticobasal Ganglionic degeneration [CBGD]
82- Stiff Person Syndrome developing into Corticobasal Syndrome: a case report.
106- Preventing Treatment Disruptions: The Crucial Role of Outpatient Nurses and Multidisciplinary Collaboration in Managing Skin Complications during Foslevodopa/Foscarbidopa Therapy
133- A case of progressive supranuclear palsy followed by dementia with Lewy bodies
135- A Case of Concurrent Wilson Disease and Parkinson Disease
140- Trihexyphenidyl Use in a Parkinsonian Phenotype of Gerstman-Sträussler-Scheinker Syndrome
143- Early-onset Parkinsonism as Presenting Manifestation of CADASIL in a Mexican Woman with NOTCH3 c.1732C>T Pathogenic Variant
145- Perry Syndrome due to a DCTN1 novel variant
149- Pallidotomy as a Therapeutic Option for Patients with Advanced Parkinson's Disease: Case Study
166- Case Report: An Unusual Case of Corticobasal Syndrome
177- Characterization of Autoimmune Parkinsonism. A case series
180- Delayed Parkinsonism as a Delayed Neurological Sequele in Carbon Monoxide Intoxication: A Rare Case Report
182- PSP-Like Syndrome Associated with Dysautonomic Findings as a Presentation of an Anti-Iglon5 Antibody-Related Encephalopathy
183- Giant Aneurysm Causing Parkinsonism and REM Sleep Disorder
190- Atypical Parkinsonism Secondary to Recurrent Deep Vein Thrombosis with Associated Intracranial Dural Fistula
191- Normal pressure hydrocephalus in two Parkinson’s disease patients with deep brain stimulation – co-occurrence or complication
192- Subdural Hematoma Leading to Subacute Secondary Parkinsonism
193- Parkinsonism Associated with Twinkle Gene Mutation
194- Unique Presentation of SPG 15 as Juvenile Levodopa Responsive Parkinsonism: A Case Report
195- Parkinsonism due to Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) Responsive to Carbidopa/Levodopa
204- The course of cognitive impairment in Parkinson's disease patients with Сovid-19
212- Wilson Disease Presenting as Rapidly Progressive Dementia
316- Molecular Landscape of Gastrointestinal Dysfunctions in Parkinson's Disease
325- Prevalence of Autonomic Symptoms in Mexican Population with Parkinson's Disease
333- Impairment of REM Sleep Architecture: A Potential Biomarker for Parkinson's Progression
363- Plasma NFL predicting fatigue conversion in early Parkinson’s disease
384- Reduced Thalamic Nuclei Volume May Contribute to Anxiety in Parkinson’s Disease: a 7-Tesla MRI Study
389- Gender-related Cognitive Disparities in Hispanic Patients with Parkinson's Disease: A Cross-Sectional Study
404- Dopamine agonist use and psychotic symptoms in patients with Parkinson’s disease.
413- Cognitive load in a diagnostic electrophysiologic assessment of functional tremor.
416- The Role of Cortisol  a Mediator in Influencing Cognitive Function
425- Complete Resolution of Tardive Dystonia After Bilateral Globus Pallidus Interna Deep Brain Stimulation
426- Reversing the irreversible: The application of Deep Brain Stimulation in The Syndrome of Irreversible Lithium Effectuated Neurotoxicity.
429- Quantitative EEG Analysis for Comparing Drug-Induced Parkinsonism and Parkinson's Disease
431- Bistriatal hypermetabolism on 18-FDG PET-CT in tardive dyskinesia
432- Tardive Dystonia Following Risperidone Treatment :  A Case Report and Therapeutic Approach
433- Acute dystonic dyskinesias in a patient used fluvoxamine. Case report
434- Central Tremor after CAR-T Cell Therapy: A Case with Neurophysiologic Characterization
437- Prevalence of Movement Disorders in Epilepsy Patients Taking Antiepileptics Drugs in a Tertiary Care Teaching Hospital in Nepal.
438- Comorbid Tardive Dyskinesia (TD) and Restless Leg Syndrome (RLS)
439- Oro-facial Dyskinesia and akathisia following Treatment by Olanzapine
440- Rare Clinical Manifestation of Tardive Dyskinesia In Schizophrenic Patient on Quetiapine and Sertraline: A Case Report
496- Depression and Cognitive Phenotype in Idiopathic Parkinson's Disease without Dementia (IPDWD). Preliminary Results of a Comparative Study of a New Scale ESDEPARK Assessing Depressive Symptomatology Specifically in IPDWD vs a General Geriatric Depression S
504- Enhancing Real-Life Gait Performance in Persons with Parkinson Disease through the Music-Based BeatWalk Application
541- Long-term Physical Exercise on Bone Mineral Density, Balance and Gait in Older Adults with Mild to Moderate Parkinson's Disease
600- Parkinson’s Disease (PD) and predictors of Driving Cessation: Results from a 6-year Longitudinal Study and a systematic review of the literature
603- "Quality of Life of Caregivers Living with a Movement Disorder. A Comprehensive Approach."
Sunday, September 29
641- Essential3: An Innovative Multi-Study Phase 3 Program to Evaluate the Efficacy and Safety of Ulixacaltamide
651- Differential Symptom Cluster Responses and Predictors to Repetitive Transcranial Magnetic Stimulation Treatment in Parkinson’s Disease:A Retrospective Study
765- Assessment of Motor and Non-Motor Alterations Impacting Functionality in Parkinson's Disease Patients
785- Design, synthesis and pharmacological evaluation of 16-pyridylmethylene derivatives of steroidal oximes as antiparkinsonian agents in MPTP-injected mice.
812- Association between Fecal Bile Acids and Levodopa Response in Patients with Parkinson’s Disease
816- Attitudes and Beliefs Towards Medication Burden and Deprescribing in Parkinson Disease
830- Adherence and Persistence Among Patients with Parkinson’s Disease Initiating Istradefylline: 12-Month Follow-Up from US Real-World Data
881- Association between statin use and mortality in Parkinson’s disease
882- A case of malignant Deep Brain Stimulation Withdrawal Syndrome treated with Opicapone
883- ECAP-Controlled Closed-Loop SCS Alleviates Neuropathic Pain and Improves Motor Function in a Patient Suffering from Parkinson’s Disease and Radicular Pain
884- Peri-Electrode Edema after Deep Brain Stimulation Implantation – Case Report and Literature Review
972- Essential Tremor: The Relationship Between Hand Dominance and Tremor Severity by MVPA
975- Neuroimaging Factors Differentially Associated with Pathology and Clinical Presentation
1043- Severity of Motor Symptoms Correlates with Asymmetric Changes in Globus Pallidus Internus and Caudate Nuclei in Parkinson’s Disease
1084- Comparative Study of Whole-Brain Functional Connectivity Patterns in Parkinson's Disease and Essential Tremor: A Resting-State fMRI Study
1090- Alterations in neural processes of cognitive control in asymptomatic heterozygous mutation carriers in the Parkin gene
1092- Emergency pallidotomy in a patient with chorea paralytica in primary hypoparathyroidism
1093- Cognitive Outcome in Pantothenate Kinase-Associated Neurodegeneration (PKAN) Treated with Deep Brain Stimulation (DBS):Case Report
1094- One-Year Outcomes of Multitarget Thalamic and Pallidal Deep Brain Stimulation in Unilateral Dystonia
1095- Deep Brain Stimulation (DBS) Improves Parkinsonism Caused by Osmotic Demyelination Syndrome (ODS)
1096- Pregnancy in Dystonia or Tourette’s patients with DBS. Eleven New Cases and a Review of the Literature.
1099- Real-World Clinical and Safety Outcomes from a Prospective, Multicenter Deep Brain Stimulation Registry of Essential Tremor Patients
1101- Impact on quality of life and nonmotor symptoms of unilateral magnetic resonance-guided focused ultrasounds (FUS) thalamotomy in patients with essential tremor.
1102- Deep Brain Stimulation of bilateral ventral intermediate nucleus in a patient with spinocerebellar ataxia type 12
1109- Botulinum Toxin and Deep Brain Stimulation in Dystonia
1115- Unveiling the Long-term Impact of Unilateral Vim DBS in Essential Tremor
1119- Deep brain stimulation of globus pallidus internus for monogenic dystonia
1120- GNAO1-related Neurodevelopmental Disorder with Involuntary Movements Inducing a Dyskinetic Status
1121- Acute Reversible Laughter with Globus Pallidus Interna Stimulation
1122- Vim DBS for Post-Stroke Tremor: A Case Report
1123- Deep brain stimulation of bilateral ventral intermediate nucleus in patients with neuronal intranuclear inclusion disease
1125- Intraoperative venous air embolism in the semi-sitting position in functional neurosurgery
1127- The Characteristics and Management of Patients with Dystonia Referred for The Troubleshooting of Deep Brain Stimulation Therapy: A Single Center Experience
1128- Holmes Tremor Treated with Pallidal Stimulation
1168- Effect of Target Selection on Mood, Pain, and Medications after DBS in PD
1173- Functional connectivity enhances prediction of STN DBS motor outcomes
1176- Longevity of Motor Benefit Achieved with Deep Brain Stimulation (DBS) of the Subthalamic Nucleus (STN) in a Single Center Cohort at the Decade Mark Post-Implantation.
1181- Early Outcomes Support use of a Remote Cross-Border Surgical Centre for Deep Brain Stimulation in Parkinson’s Disease
1186- The Challenges of Adaptive Deep Brain Stimulation: A Delphi Panel Study
1254- Identification of Fall Risk in Patients with Parkinson's Disease Through Telemonitoring
1259- Digital health technology (DHT) derived features as sensitive measures of disease progression in early Parkinson’s disease under stable dopaminergic treatment
 Monday, September 30 
1280- Spectrum of polysomnographic abnormalities in a cohort of sporadic late onset ataxia patients
1282- White Matter Tractography in Spinocerebellar Ataxia type 1 and 2 in comparison with Healthy Controls
1283- Variant Ataxia Telangiectasia: A Novel ATM Gene Mutation With Disabling Tremor and Response to Deep Brain Stimulation
1284- Novel Partial Gene Deletion in CaCNA1A Presenting with Gait Ataxia, Vertigo, and Abnormal Eye Movements
1286- Increased Risk of Suicidal Ideation in Patients with Spinocerebellar Ataxias
1289- Spinocerebellar ataxia type 2 (SCA2) and Seizures: Is There a Correlation?
1291- Progressive Myoclonic Ataxia: Neuroinflammation and Autoantibodies Against Inhibitory Synapses and Herpes Viruses
1294- Pulmonary Dysfunction in Friedreich's Ataxia (FRDA)
1298- Association of expanded CAG repeat with autonomic function in Spinocerebellar Ataxia Type-2 (SCA-2)
1300- Clinical and Genetic Profile of Spinocerebellar Ataxias in a Tunisian Cohort
1302- Prevalence of Heterozygous ATP7B Mutation in Patients with Movement Symptoms
1305- Electrophysiological study of 122 Tunisian patients with autosomal recessive cerebellar ataxia
1307- NGS diagnosis rate in a combined cerebellar ataxia and spastic paraplegia series from southern Spain
1311- Substantia Nigra Degeneration In Spinocerebellar Ataxia 2 And 7 Using Neuromelanin-Sensitive Imaging
1312- Ataxia, tremor, fasciculations and hemiparesis in a GBA1 heterozygous female carrier
1314- Oculomotor Biomarkers for Cerebellar Ataxia and Severity in Smooth Pursuit
1316- Alterations in the Daily Living Gait and Mobility during the Day and Night among Individuals with Cerebellar Ataxia, SCA3: An Exploratory Study
1317- Spinocerebellar Ataxia Type 49 presenting with Early onset Dystonia-Ataxia in an Indian Female
1324- Predicting Disease Severity in Friedreich's Ataxia through Wearable Monitoring and Machine Learning.
1325- CAPRIN1 defect: a new severe neurodegenerative disorder with childhood dementia, myoclonus-ataxia, and sensorimotor neuropathy
1328- paraneoplastic cerebellar ataxia: a rare cause of late-onset ataxia
1330- Effects of Transpinal Magnetic Stimulation (TsMS) in Patients Diagnosed with Spinocerebellar Ataxia 3 (SCA 3)
1331- Seminoma resulting in rapidly progressive cerebellar syndrome with associated dual positive kelch-like protein 11 (KLHL11) IgG and leucine zipper 4 (LUZP4)–immunoglobulin G (IgG) antibodies.
1332- Superficial siderosis; a case review
1333- Diagnostic challenges with novel SCA variants: A case of STUB1 mutation
1334- Spastic Ataxia Associated with Congenital Myasthenia Related to the VAMP1 Gene: Report of an Affected Family in Brazil.
1335- Transcranial Direct Current Stimulation and Neurofunctional Physical Therapy Improves Motor and Cognitive Symptoms in a Patient with Type 1 Spinocerebellar Ataxia – A Case Report
1336- Movement disorders secondary to neurocysticercosis: a  case report from Bolivia
1338- Volatile solvent abuse and Cerebellar ataxia: A case series
1340- Friedreich’s ataxia: A descriptive study of a Tunisian cohort
1341- Progressive cerebellar ataxia in primary Sjögren’s syndrome: a case report
1343- A study on the phenomenological analysis of Spinocerebellar Ataxia type 12 revealing a dystonic imprint
1350- Ektacytometry in Neuroacanthocytosis
1351- A Novel Mutation of NKX2-1 Gene: A Rare Presentation of Chorea
1355- The clinical features, neuroimagings and outcomes of diabetic striatopathy: a retrospective study at tertiary hospital in Vietnam
1358- Spectrum of Non-HD Hereditary Chorea- Case Series from An Indian Movement Disorder Centre
1360- A Rare Case of Hemicorea Secondary to Giant Perivascular Space: A Case Report
1361- Clonazepam as First-Line Therapy for Post-Hypoxic Chorea: A Case Report and Discussion
1363- Chorea Acanthocytosis Misdiagnosed as Functional Movement Disorder
1364- Bilateral Fronto-Temporal Lobar Atrophy: An Atypical Magnetic Resonance Imaging Finding in Neuroacanthocytosis
1365- Hyperkinetic Movements Related to COVID-19 Vaccine
1366- Fahr's Disease Presenting as Chorea: A Rare Case Report
1367- Reversible Hemichorea-Hemiballismus-Hemifacial Spasm in Diabetic Striatopathy
1368- Choreoacanthocytosis: The First Genetically Confirmed Cases From Algeria
1369- Cortical Pencil Lining in Brain MRI of a Patient with Chorea and Hepatic Cirrhosis
1370- Acute Chorea in The Emergency Department Related to Systemic Lupus and Antiphospholipid Syndrome: A Case Report
1371- Diabetic striatopathy with stroke - like symptoms: A case report
1372- Severe chorea, ballistic and dystonic movement disorder due to intracerebral hemorrhage in subthalamic nucleus
1379- The Impact of Standardized Recommendations on the Management of Initial and Refractory Pediatric Status Dystonicus
1382- Deep Brain Stimulation in Dystonia: Investigating Differential Response by Dystonia Distribution
1388- Do Lower Doses of Botulinum Neurotoxin Type-A Offer a Longer Duration of Effect and Superior Efficacy in Patients with Cervical Dystonia?
1404- Real-World Diagnosis of Chronic Migraine in Patients With Cervical Dystonia Analyzed by Botulinum Neurotoxin Treatment Exposure: an Epidemiologic Perspective
1406- KMT2B-Related Dystonia And DBS: Tertiary Center Experience
1407- Clinical Outcomes and Local Field Potential Characteristics in Bilateral GPi DBS in 2 cases of X-Linked Dystonia Parkinsonism
1409- Clinical Characteristics and Management Practices of Pediatric Status Dystonicus
1410- Genetic Variant in the VPS16 Gene in a 44-year-old Patient with Generalized Dystonia
1417- Cervical dystonia after cerebellar stroke and medullary hemorrhage
1418- Challenges in Wilson disease management in a resource-limited country: a case report from a tertiary center
1420- Oromandibular Dystonia in Hashimoto Encephalopathy: An Unusual Association Not To Miss
1422- Expanding the concept of “occupational dystonia”: data from the Italian Dystonia Registry
1431- Increased cerebellar grey matter in writer’s cramp patients: a morphometric signature of symptom compensation
1435- Writing dysfluency associates with basal ganglia network dysfunction in writer’s cramp dystonia
1466- Treatment Effect Sizes of Once-Daily Valbenazine for Tardive Dyskinesia and for Chorea Associated with Huntington’s Disease: A Post-Hoc Analysis of Phase 3 Clinical Trial Data
1484- The Spectrum of Presenting Phenotypes in Childhood Onset Huntingtons Disease
1486- Closed-Loop Spinal Cord Stimulation: A Case Report on a Novel Therapeutic Approach for Post-Hypoxic Myoclonus
1487- Treatment of Post-hypoxic Myoclonus using Bilateral Subthalamic Nuclei Deep Brain Stimulation
1490- Cortical myoclonus in DHDDS: the multifaced presentation of a single movement disorder
1492- Mechanism Study of Familial Cortical Myoclonic Tremor with Epilepsy Type 1 Caused by Pentanucleotide Repeat Expansion in the SAMD12 Gene
1493- Childhood onset progressive myoclonus and ataxia in a patient with novel TBC1D2B gene mutation
1502- Benzodiazepines in the Management of Restless Legs Syndrome: A Systematic Review and Meta-Analysis
1522- Ultrasound Assessment of Collagen Content in Contracted and Non-contracted Muscle Areas: A Comparative Study
1533- Contribution to Efficacy by Active Metabolites of Suvecaltamide in a Preclinical Rat Model of Essential Tremor
1546- Dentato-Rubro-Thalamic Tract Deep Brain Stimualtion for Essential Tremor: Stimulation Parameters and Clinical Outcomes
1559- Prevalence of Phosphorylated Alpha-Synuclein in Skin Biopsies of Essential Tremor Patients
1564- Sleep profiles in patients with Essential Tremor and Essential Tremor Plus: Polysomnography Insights
1573- Evaluating the Effect of Myofascial Release on Parkinson's Related Tremor
1576- Is essential tremor-plus phenotype a prodromal phase of Parkinson’s disease ?
1580- Application of Neurophysiology in the Clinical Evaluation of Pediatric and Adolescent Patients with Tremor
1581- Movement Disorders Associated with Infectious Encephalitis in Pediatric Patients
1587- Identification and Screening of Candidate Genes for Paroxysmal Movement Disorders by Next Generation Sequencing Approach for Developing Molecular Diagnostics.
1589- Improving Work Up amongst Patients with Rare Movement Disorders according to Diagnostic Yield Findings– Update from Single Center Neurogenetic Clinic
1595- Three-Year Progression of the Postural Control Alterations in Hereditary Spastic Paraplegias
1597- Expanding the phenotypic spectrum of movement disorders in 22q11.2 deletion syndrome
1598- A Novel SLC9A1 Mutation Associated with Cerebellar Ataxia and Sensorineural Hearing Loss
1599- Parkinsonism in combined Fragile X and XYY Syndromes: A Case Report
1600- Clinico- radiological profile of four patients with CSF1R- related leukoencephalopathy: A case series from India
1604- Intermediate Expansion of MARCHF6 causes FAME3 without Epilepsy
1606- Validation of Inertial Measurement Units and an application compared with the reference system to assess the gait in hereditary spastic paraplegia
1607- OPTN gene associated with corticobasal syndrome: a novel multi-exon deletion and literature review
1619- Association of Gaucher-related and Parkinson’s-private GBA1 variants with progression of PD: A longitudinal mixed model analysis.
1629- Disease Progression in Patients with PLA2G6-related Parkinsonism: A Longitudinal Study
1636- Differences in Oculometric Measures between Patients with LRRK2-associated and Idiopathic Parkinson’s Disease
1668- Genetic Analysis of Mendelian mutations in A Large Chinese Early-onset and Familial Parkinson’s Disease
1681- The Black and African American Connections to Parkinson’s Disease Study
1692- The association of Severity and Monogenetic Subgroups in Parkinson's Disease
1693- 7year followup of Asia’s first case of sporadic ATP6AP2 Mutation: α-synucleinopathy or tauopathy?
1694- Expanding Phenotype of LRRK2 G2019S Mutation: Case Description of Two Sisters Showing Peculiar Phenomenological Traits
1695- A Case of Paradoxical Gait Response to Levodopa in Parkin-Gene-Related Early-Onset Parkinson's Disease
1696- Adding Parkinsonism to the Phenotypic Spectrum of FIG4-related diseases
1697- A new phenotype-genotype correlation for FIG4 gene and Parkinson's disease
1700- Novel ASO Targeting IGHMBP2 Cryptic Splice Variant: Efficacy and Safety
1703- Wilson's Disease : A Senegalese Series of Seven Patients Followed at Pikine National Hospital Centre (Dakar-Senegal)
1704- DPPX Autoimmune Encephalitis Associated with Severe Multifocal Dystonia.
1705- A Patient with Overlapping SPG7 mutation and MERRF
1712- Association between Hyperglycemic Crisis Severity and Movement Disorders in Hispanic Patients with De Novo Hyperglycemia: A Cross-Sectional Study
1725- Mutation of the ATP5F1A gene associated with dystonia, spasticity, myoclonus, cognitive impairment and epilepsy –  a rare case report of a patient
1727- Movement Disorders in Cerebrotendinous Xanthomatosis
1729- Movement Disorders in De Novo Hyperglycemic Crisis: Insights from a Clinical Case Series
1730- A Unique case of Ataxia, Neuropathy, and chronic cough: CANVAS
1731- Startle Reflex in CTNNB1 Mutations: A diagnostic Clue
1732- Dopa-responsive ataxia with compound heterozygous variants in MRE11
1733- Phenotypic variability of mitochondrial tRNA Ser(UCN) gene [MTTS1] mutation: First report from India
1734- PMM2 mutation
1735- Spastic Ataxia and Motorneuron disease as possible manifestations of ATP13A2 (PARK 9) variants
1736- Phenomenology of Coenzyme Q10-deficiency Spinocerebellar Ataxia: Case Description Of Two Siblings And New Therapeutic Perspectives
1743- Complexity of fractal patterns in motor cortical oscillatory activity in rodent models of Parkinson disease
1754- Clinical, Neurophysiological, and Biological Insights into Levodopa-Induced Dyskinesias
1764- Correlation of Neural Sensing with the Volume of Neural Activation within the Desired Patient-Specific Anatomical Target in Deep Brain Stimulation for Parkinson’s Disease
1765- Levels of change in interleukin-6 levels according to clinical forms of Parkinson's disease in patients with and without Covid-19
1770- Quantification of an Upper Limb Rigidity Network in Parkinson Disease
1821- Pregnancy and delivery in women with Parkinson’s disease:  A case series
1844- Free-Viewing Eye Tracking and the Effect of Levodopa in Parkinson’s Disease
1845- Evaluation of unsteadiness in patients with dystonia
1849- Apraxia of eyelid opening in patients with movement disorders
1862- Engage, Educate and Empower: Parkinson’s Research Advocates from the Black and African American Community
1880- Behind the Prison Gates - Creating a nurse led Parkinson’s healthcare pathway at HMP Dartmoor Prison, UK.
1889- Antibody-mediated movement disorders: a single-centre retrospective study
1901- Movement Disorders in the Emergency:New Insights
1905- Tremors Vs. Tremors: the first music album from Parkinson’s tremors
1909- Seeking Traditional Healers in Movement Disorders: a pilot study in two African Countries
1915- Demographics of Botulinum toxin therapy population representative to demographics in Essex County, USA
1916- Dandy-Walker syndrome. A case study.
1917- Wilson's Disease About A Complex Case
1922- PD Young Ambassadors: A Peer-led, Community-Based Intervention to Raise PD Awareness in the Hispanic Communities of Chicago.
1923- Adult Onset Spastic Paraplegia in TUBB4A Leukodystrophy

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice